Reminder for Soleno Therapeutics Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Should l Buy SLNO?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns regarding its DCCR drug during clinical trials, leading to increased commercial risks and potential legal repercussions, which negatively impacted investor confidence and the company's stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its extensive experience and success in handling such cases.
- Investor Action Advice: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to ensure optimal representation in the lawsuit.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.950
Low
75.00
Averages
110.50
High
125.00
Current: 52.950
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the pending securities class action against Soleno Therapeutics (NASDAQ:SLNO), with a lead plaintiff deadline of May 5, 2026, for those who purchased shares between March 26, 2025, and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, resulting in significant investor losses due to concealed risks.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 results admitting disruptions in DCCR's launch, leading to a 27% drop in stock price in a single day, reflecting market disappointment in the company's prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to assist in the investigation, as whistleblowers may receive rewards of up to 30% of any successful SEC recovery, further advancing legal actions against Soleno.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies like Select Medical Holdings, XOMA Royalty Corporation, Soleno Therapeutics, and KORE Group Holdings for potential violations of federal securities laws and fiduciary duties, which may impact shareholder rights.
- Select Medical Transaction: Shareholders of Select Medical may face a sale to a consortium led by executives at $16.50 per share, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures to protect shareholder interests.
- XOMA Royalty Transaction: XOMA Royalty Corporation shareholders are set to sell to Ligand Pharmaceuticals for $39.00 per share, and Halper Sadeh LLC may advocate for higher transaction prices and transparency to ensure shareholders' legal rights are upheld.
- Soleno and KORE Transactions: Soleno Therapeutics shareholders will sell to Neurocrine Biosciences for $53.00 per share, while KORE Group Holdings shareholders will sell to Searchlight Capital Partners and Abry Partners for $9.25 per share, with Halper Sadeh LLC providing legal support to ensure these shareholders' rights are protected.
See More
Soleno Therapeutics Faces Class Action Lawsuit
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Soleno Therapeutics, alleging securities fraud by the company and certain officers, with investors needing to apply as Lead Plaintiff by May 5, 2026, indicating significant legal risks for the firm.
- Stock Price Volatility: On August 15, 2025, Soleno's stock fell by 7.41% to $71.63 after Scorpion Capital's report criticized its only product, DCCR, as overpriced and potentially unsafe for children, reflecting market concerns over product safety.
- Patient Death Incident: Following the disclosure on September 10, 2025, of a patient death linked to DCCR, Soleno's stock plummeted by 19.21% over the next two trading sessions to close at $56.72, highlighting the potential legal and reputational risks facing the company.
- Rising Discontinuation Rates: During the earnings call on November 4, 2025, Soleno's CEO revealed an 8% discontinuation rate for DCCR due to adverse effects, stating that the Scorpion report disrupted the product's launch trajectory, leading to a further 26.59% drop in stock price to $46.87, indicating declining market confidence in the company's future.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the lead plaintiff deadline on May 5, 2026, for the securities class action against Soleno Therapeutics (NASDAQ:SLNO), concerning those who purchased shares between March 26, 2025, and November 4, 2025.
- Concealed Safety Risks: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, leading to significant investor losses due to undisclosed risks.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 results admitting disruptions in DCCR's launch, causing a 27% drop in stock price in a single day, reflecting market disappointment in its commercial prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, to assist in the investigation of Soleno's practices.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ: SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share, which may involve violations of shareholder rights.
- Shareholder Rights Protection: The transaction between Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) and Biogen Inc. includes $41.00 per share in cash and two non-transferable rights of $2.00 each, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures for shareholders.
- Merger Impact: Helix Energy Solutions Group, Inc. (NYSE: HLX) is merging with Hornbeck Offshore Services, Inc., resulting in Helix shareholders owning approximately 45% of the combined entity, prompting Halper Sadeh LLC to assess the implications for shareholders.
- Legal Fee Arrangement: Halper Sadeh LLC offers legal services on a contingency fee basis, allowing shareholders to consult on their rights and options without upfront costs, ensuring their legal interests are protected.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the pending securities class action against Soleno Therapeutics (NASDAQ:SLNO), with a lead plaintiff deadline of May 5, 2026, for those who purchased shares between March 26, 2025, and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, resulting in significant investor losses due to concealed risks.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 results admitting disruptions in DCCR's launch, leading to a 27% drop in stock price in a single day, reflecting market disappointment in the company's prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to assist in the investigation, as whistleblowers may receive rewards of up to 30% of any successful SEC recovery, further advancing legal actions against Soleno.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies like Select Medical Holdings, XOMA Royalty Corporation, Soleno Therapeutics, and KORE Group Holdings for potential violations of federal securities laws and fiduciary duties, which may impact shareholder rights.
- Select Medical Transaction: Shareholders of Select Medical may face a sale to a consortium led by executives at $16.50 per share, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures to protect shareholder interests.
- XOMA Royalty Transaction: XOMA Royalty Corporation shareholders are set to sell to Ligand Pharmaceuticals for $39.00 per share, and Halper Sadeh LLC may advocate for higher transaction prices and transparency to ensure shareholders' legal rights are upheld.
- Soleno and KORE Transactions: Soleno Therapeutics shareholders will sell to Neurocrine Biosciences for $53.00 per share, while KORE Group Holdings shareholders will sell to Searchlight Capital Partners and Abry Partners for $9.25 per share, with Halper Sadeh LLC providing legal support to ensure these shareholders' rights are protected.
See More
Soleno Therapeutics Faces Class Action Lawsuit
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Soleno Therapeutics, alleging securities fraud by the company and certain officers, with investors needing to apply as Lead Plaintiff by May 5, 2026, indicating significant legal risks for the firm.
- Stock Price Volatility: On August 15, 2025, Soleno's stock fell by 7.41% to $71.63 after Scorpion Capital's report criticized its only product, DCCR, as overpriced and potentially unsafe for children, reflecting market concerns over product safety.
- Patient Death Incident: Following the disclosure on September 10, 2025, of a patient death linked to DCCR, Soleno's stock plummeted by 19.21% over the next two trading sessions to close at $56.72, highlighting the potential legal and reputational risks facing the company.
- Rising Discontinuation Rates: During the earnings call on November 4, 2025, Soleno's CEO revealed an 8% discontinuation rate for DCCR due to adverse effects, stating that the Scorpion report disrupted the product's launch trajectory, leading to a further 26.59% drop in stock price to $46.87, indicating declining market confidence in the company's future.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the lead plaintiff deadline on May 5, 2026, for the securities class action against Soleno Therapeutics (NASDAQ:SLNO), concerning those who purchased shares between March 26, 2025, and November 4, 2025.
- Concealed Safety Risks: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, leading to significant investor losses due to undisclosed risks.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 results admitting disruptions in DCCR's launch, causing a 27% drop in stock price in a single day, reflecting market disappointment in its commercial prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, to assist in the investigation of Soleno's practices.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ: SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share, which may involve violations of shareholder rights.
- Shareholder Rights Protection: The transaction between Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) and Biogen Inc. includes $41.00 per share in cash and two non-transferable rights of $2.00 each, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures for shareholders.
- Merger Impact: Helix Energy Solutions Group, Inc. (NYSE: HLX) is merging with Hornbeck Offshore Services, Inc., resulting in Helix shareholders owning approximately 45% of the combined entity, prompting Halper Sadeh LLC to assess the implications for shareholders.
- Legal Fee Arrangement: Halper Sadeh LLC offers legal services on a contingency fee basis, allowing shareholders to consult on their rights and options without upfront costs, ensuring their legal interests are protected.
See More
